Mother-to-neonate transfer of anti-SARS-CoV-2 antibodies significantly lower than anti-influenza hemagglutinin A antibody transfer
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, Dec. 23, 2020 (HealthDay News) -- There is no evidence of placental infection or vertical transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study published online Dec. 22 in JAMA Network Open.
Andrea G. Edlow, M.D., from Massachusetts General Hospital in Boston, and colleagues quantified SARS-CoV-2 viral load in maternal and neonatal biofluids, transplacental passage of anti-SARS-CoV-2 antibody, and incidence of fetoplacental infection in a cohort study involving 127 pregnant women. Overall, 64 and 63 of the women were positive and negative, respectively, for SARS-CoV-2 by reverse transcription-polymerase chain reaction testing.
The researchers observed no detectable viremia in maternal or cord blood and no evidence of vertical transmission in viral load analyses among 107 women. One of 77 neonates tested in whom SARS-CoV-2 antibodies were quantified in cord blood had detectable immunoglobulin M to nucleocapsid. SARS-CoV-2 RNA was not detected in any of the 88 placentas tested. Of 37 women with SARS-CoV-2 infection who underwent antibody analyses, 65 and 70 percent had anti-receptor-binding domain immunoglobulin G and anti-nucleocapsid, respectively. Transfer of anti-SARS-CoV-2 antibodies from mother to neonate was significantly lower than anti-influenza hemagglutinin A antibody transfer (mean cord-to-maternal ratio: 0.72, 0.74, and 1.44 for anti-receptor-binding domain immunoglobulin G, anti-nucleocapsid, and anti-influenza, respectively).
"Our finding of compromised mother-to-baby transfer of SARS-CoV-2-specific antibodies in third trimester infections has implications for maternal vaccine administration," Edlow said in a statement. "Specifically, it highlights that pregnant women are a key population to consider in vaccine rollouts."
Several authors disclosed financial ties to the biopharmaceutical and medical technology industries.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 25, 2022
Read this Next
Other Trending Articles